Biomarker for Pompe Disease (BioPompe)

Sponsor

CENTOGENE GmbH Rostock (Industry)

Overall Status

Active, not recruiting

CT.gov ID

NCT01457443

Collaborator

(none)

1,000

Enrollment

Locations

35.4

Anticipated Duration (Months)

250

Patients Per Site

7.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Development of a new MS-based biomarker for the early and sensitive diagnosis of Pompe disease from blood (plasma)

Condition or Disease	Intervention/Treatment	Phase
Cardiac Diseases Muscular Weakness Hepato-splenomegaly Lung Disease Obstructive Sleep Apnoea Macroglossia Cerebral Aneurysm

Detailed Description

Pompe disease is a rare (estimated at 1 in every 40,000 births), inherited and often fatal disorder that disables the heart and muscles. It is caused by mutations in a gene that encodes an enzyme called alpha-glucosidase (GAA). Normally, the body uses GAA to break down glycogen, the long-term storage form of sugar, into glucose, which the body can utilize to gain energy. But in Pompe disease, mutations in the GAA gene reduce or completely eliminate the activity of this essential enzyme. Excessive amounts of glycogen accumulate everywhere in the body, but the cells of the heart and skeletal muscles are the most seriously affected. Re-searchers have identified up to 70 different mutations in the GAA gene that cause the symptoms of Pompe disease, which can vary widely in terms of age of onset and severity. The severity of the disease and the age of onset are related to the degree of enzyme deficiency.

Early onset (or infantile) Pompe disease is the result of complete or near complete deficiency of GAA. Symptoms begin in the first months of life, with feeding problems, poor weight gain, muscle weakness, floppiness, and head lag. Respiratory difficulties are often complicated by lung infections. The heart is grossly enlarged. More than half of all infants with Pompe disease also have enlarged tongues. Most babies with Pompe disease die from cardiac or respiratory complications before their first birthday.

Late onset (or juvenile/adult) Pompe disease is the result of a partial deficiency of GAA. The onset can be as early as the first decade of childhood or as late as the sixth decade of adulthood. The primary symptom is muscle weakness progressing to respiratory weakness and death from respiratory failure after a course lasting several years. The heart may be involved but it will not be grossly enlarged. A diagnosis of Pompe disease can be confirmed by screening for the common genetic mutations or measuring the level of GAA enzyme activity in a blood sample - a test that has 100 percent accuracy. Once Pompe disease is diagnosed, testing of all family members and consultation with a professional geneticist is recommended. Carriers are most reliably identified via genetic mutation analysis.

New methods, like mass-spectrometry give a good chance to characterize in the blood (plasma) of affected patents specific metabolic alterations that allow to diagnose in the future the disease earlier, with a higher sensitivity and specificity.

Therefore it is the goal of the study to develop new biochemical markers from the plasma of the affected patients helping to benefit the patient by an early diagnose and thereby with an earlier treatment.

Study Design

Study Type:

Observational

Anticipated Enrollment :

1000 participants

Observational Model:

Cohort

Time Perspective:

Prospective

Official Title:

Biomarker for Pompe Disease AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGI-CAL PROTOCOL

Actual Study Start Date :

Aug 20, 2018

Anticipated Primary Completion Date :

Aug 1, 2021

Anticipated Study Completion Date :

Aug 1, 2021

Arms and Interventions

Arm	Intervention/Treatment
Observation Patients with Pompe disease

Outcome Measures

Primary Outcome Measures

Development of a new MS-based biomarker for the early and sensitive diagnosis of Pompe disease from plasma [24 month]
New methods, like mass-spectrometry give a good chance to characterize specific metabolic alterations in the blood of affected patients that allow diagnosing in the future the disease earlier, with a higher sensitivity and specificity

Secondary Outcome Measures

Testing for clinical robustness, specificity and long-term stability of the biomarker [36 months]
the goal of the study to identify and validate a new biochemical marker from the blood of the affected patients helping to benefit other patients by an early diagnose and thereby with an earlier treatment.

Eligibility Criteria

Criteria

Ages Eligible for Study:

12 Months and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Informed consent will be obtained from the patient or the parents before any study related procedures.
Patients older than 12 months
The patient has a diagnosis of Pompe disease

Exclusion Criteria:

No Informed consent from the patient or the parents before any study related procedures
Patients younger than 12 months
The patient has no diagnosis of Pompe disease

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Centogene AG	Rostock		Germany	18055
2	Amrita Institute of Medical Sciences & Research Centre	Cochin	Kerala	India	682041
3	Navi Mumbai Institute of Research In Mental And Neurological Handicap (NIRMAN)	Mumbai		India	400705
4	Lady Ridgeway Hospital for Children	Colombo 8		Sri Lanka	00800c